Zosano Announces Inducement Grant for Georgia Erbez, Chief Business Officer
10 9월 2016 - 6:00AM
Zosano Pharma Corporation (NASDAQ:ZSAN), an emerging CNS company
focusing on providing rapid symptom relief to patients using the
Company’s proprietary transdermal delivery system, today announced
that it has approved an inducement grant of options to purchase
252,000 shares of the Company’s common stock with an exercise price
of $0.77 per share, the closing price on September 7, 2016, to
Georgia Erbez, the Company's recently hired Chief Business Officer.
The stock options have a ten year term and vest over four years,
with one-fourth vesting on the first anniversary of the date of
grant and the remaining three-fourths vesting in equal monthly
installments thereafter.
The grant was made as an inducement that was a material
component of Ms. Erbez's compensation and subsequent acceptance of
employment with the Company and was granted as an employment
inducement award pursuant to Nasdaq Listing Rule 5635(c)(4)
approved by the Company's Compensation Committee.
About Zosano Pharma
Zosano Pharma Corporation is an emerging CNS company focusing on
providing rapid symptom relief to patients using known therapeutics
and altering their delivery profile using the Company’s proprietary
transdermal delivery system. The Company’s goal is to make
transdermal drug delivery a standard of care for delivering drugs
requiring fast onset of action. Zosano Pharma has developed its
proprietary transdermal delivery system to administer novel
formulations of existing drugs through the skin for the treatment
of a variety of indications. The Company believes that its
transdermal delivery system offers rapid and consistent drug
delivery combined with ease of use. The Company is focused on
developing products that deliver established molecules with known
safety and efficacy profiles for markets where patients remain
underserved by existing therapies. Zosano Pharma anticipates
that many of its current and future development programs may enable
the Company to utilize a regulatory pathway that would streamline
clinical development and accelerate the path towards
commercialization. Learn more at www.zosanopharma.com.
Zosano Contact:
Konstantinos Alataris, Ph.D.
Chief Executive Officer
510-745-1200
Investor Contact:
Jamien Jones
Blueprint Life Science Group
415-375-3340 x 5
jjones@bplifescience.com
Zosano Pharma (NASDAQ:ZSAN)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Zosano Pharma (NASDAQ:ZSAN)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024
Zosano Pharma Corporation (나스닥)의 실시간 뉴스: 최근 기사 0
More News Articles